Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355567 | 0.98 | GSK3B (0.33) | GSK3BMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17077819 | 0.77 | SMN1; SMN2 (0.34) | ALDH1A1 | |
| SCHEMBL18356096 | 0.73 | EPHX2 (0.34) | — | |
| SCHEMBL6115382 | 0.67 | GSK3B (0.34) | GSK3BMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2097340 | 0.65 | HDAC6 (0.50) | ALDH1A1MAPT | |
| SCHEMBL6115345 | 0.63 | GSK3B (0.34) | GSK3B | |
| SCHEMBL12926025 | 0.62 | — | — | |
| SCHEMBL10949773 | 0.62 | KDM4E (0.41) | GSK3BMAPTKMT2A | |
| Bromide SCHEMBL6075738 | 0.62 | NAMPT (0.41) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18356298 | 0.61 | ATM (0.36) | GSK3BMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116858-B1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2020-11-11 | — | — | EP | disclosed |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2018-11-29 | — | — | US | disclosed |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2018-10-09 | — | — | US | disclosed |
| EP-3116858-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc. (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| WO-2015136947-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | GSK3B 2725/4885MEN1 776/4885ALDH1A1 2024/4885 |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | TRPM8, TRPM7, TRPM5 | GSK3B 2725/4885MEN1 776/4885ALDH1A1 2024/4885 |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM6 | GSK3B 2584/4885MEN1 841/4885ALDH1A1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.